"Robert Rudolph knew he was about to end his lucrative career at Eli Lilly & Co., but he had to say something.
Why, he asked management, was the Indianapolis pharmaceutical company marketing its antipsychotic drug Zyprexa to elderly people when the drug was not approved for that group?
Why had the company violated privacy rules by culling patient lists at doctors' offices?
Why was the company counting drug samples as sales, which would boost the stock price?
He went on for about 10 minutes during a sales meeting in 2002. The other 25 Lilly sales representatives stared at him, stunned.
'I'd just been wrestling with this stuff for so long," he said in a telephone interview today. 'I was put in a position of breaking the law, in my view, or quitting.'"
Read more in The Philadelphia Inquirer.